|
|
|
|
EligardCanada NewsWire (press release), TAP and its co-plaintiffs had sued QLT USA and Sanofi-Synthelabo in 2003 alleging that QLT USA's Eligard(R) products infringe a TAP patent which expires in May ... QLT Announces Partial Result in Eligard Patent Litigation Dec 15, 2005 ag-IP-news Agency, TAP and its co-plaintiffs had sued QLT USA and Sanofi-Synthelabo in 2003 alleging that QLT USA's Eligard products infringe a TAP patent which expires in May ... Sosei Business Update and Revised Financial Forecast Following ... Dec 15, 2005 Canada NewsWire (press release), Key Updates from the Development Pipeline Eligard - is a long acting formulation of the LHRH agonist leuprorelin. Sosei submitted ... Sosei Business Update and Revised Financial Forecast Following ... Dec 15, 2005 PR Newswire (press release), Eligard - is a long acting formulation of the LHRH agonist leuprorelin. Sosei submitted its application for the regulatory approval ... US jury hands QLT a setback in lengthy drug patent battle Dec 15, 2005 Vancouver Sun (subscription), But the battle over the company's ability to sell its prostate cancer drug, Eligard, is far from over, QLT's senior vice-president and principal legal officer ... QLT announces departure of chief business officer Dec 22, 2005 CNW Telbec (Communiqués de presse), ...drug therapies with our two unique technology platforms, photodynamic therapy and Atrigel(R), to create products such as Visudyne(R) and Eligard(R). For more ... Medigene issues non-exclusive license to Glaxo; receives one-time ... Dec 19, 2005 Forbes The German biotech company said that this payment, in combination with sales of its prostate cancer drug Eligard, 'will ensure that MediGene will reach its ... Sosei "equal weight," target price reduced Dec 19, 2005 New Ratings The scheduled approval for Sosei’s Eligard drug has been delayed to after next March, which pushes back the launch of the drug to FY09, the analysts add. QLT announces departure of chief business officer Dec 21, 2005 Yahoo! News (press release) ...of innovative drug therapies with our two unique technology platforms, photodynamic therapy and Atrigel®, to create products such as Visudyne® and Eligard®. ... MediGene Receives One-Time Payment for License Agreement with ... Dec 19, 2005 Biotech Intelligence (press release), The payment from Glaxo, combined with Eligard® sales, will ensure that Medigene will reach previous established guidance for 2005 of revenues of 20 million EUR ... QLT cuts 100 jobs Dec 22, 2005 Globe and Mail, Pharmaceutical Products Inc. in an early ruling in a patent lawsuit over QLT's Eligard treatment for pancreatic cancer. QLT shares ... Bachem Double Disappointment Underscores Risk Dec 15, 2005 New Ratings Bachem makes Zadaxin. Elsewhere, QLT (QLTI) loses a round of patent litigation over Eligard, also made by Bachem. Though this won ... Other News To Note Dec 20, 2005 TMCnet The payment, combined with sales of Eligard, MediGene's prostate cancer drug, aims to ensure that MediGene will reach its previously established 2005 guidance ... (PRN) - Reveleus Selected by Lloyds TSB's Securitisation Team to ... Dec 14, 2005 Bolsamania.com, Issued as Stock Options ... [+. PRN) - QLT announces partial result in Eligard(R) patent litigation ... [+. PRN) - Ford President ... |
|
Home Copyright phasechange.org 2006. All Rights Reserved. |